Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress

Christopher G.A. Price , Ama Z.S. Rohatiner , William Steward , David Deakin , Nigel Bailey , Andrew Norton , George Blackledge , Derek Crowther , T. Andrew Lister
{"title":"Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: Preliminary results of a randomized trial in progress","authors":"Christopher G.A. Price ,&nbsp;Ama Z.S. Rohatiner ,&nbsp;William Steward ,&nbsp;David Deakin ,&nbsp;Nigel Bailey ,&nbsp;Andrew Norton ,&nbsp;George Blackledge ,&nbsp;Derek Crowther ,&nbsp;T. Andrew Lister","doi":"10.1016/0277-5379(91)90567-W","DOIUrl":null,"url":null,"abstract":"<div><p>One hundred and twenty four patients with follicular lymphoma (32 with Stage III and 92 with Stage IV disease) have been randomized to receive chlorambucil alone or chlorambucil plus interferon alfa-2b. Responding patients are then randomized to receive either interferon alfa-2b maintenance therapy for up to 12 months or no further treatment. One hundred and eight patients are evaluable for response, the remainder are still receiving initial therapy. Clinical remission (complete or good partial remission) was achieved in <span><math><mtext>42</mtext><mtext>59</mtext></math></span> (71%) patients receiving chlorambucil alone and in <span><math><mtext>27</mtext><mtext>49</mtext></math></span> (55%) patients receiving the combination (<em>P</em> = NS). Preliminary analysis of remission duration shows a trend in favour of those patients receiving interferon throughout (<em>P</em> = 0.02). There is no significant difference between the groups in terms of survival, at a median follow up of 2.5 years. Interferon-associated toxicity was minor in most patients but led to discontinuation of therapy in six cases. Larger trials with longer follow-up periods are needed to confirm the beneficial role of interferon in the treatment of follicular lymphoma.</p></div>","PeriodicalId":11925,"journal":{"name":"European Journal of Cancer and Clinical Oncology","volume":"27 ","pages":"Pages S34-S36"},"PeriodicalIF":0.0000,"publicationDate":"1991-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0277-5379(91)90567-W","citationCount":"22","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Cancer and Clinical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/027753799190567W","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 22

Abstract

One hundred and twenty four patients with follicular lymphoma (32 with Stage III and 92 with Stage IV disease) have been randomized to receive chlorambucil alone or chlorambucil plus interferon alfa-2b. Responding patients are then randomized to receive either interferon alfa-2b maintenance therapy for up to 12 months or no further treatment. One hundred and eight patients are evaluable for response, the remainder are still receiving initial therapy. Clinical remission (complete or good partial remission) was achieved in 4259 (71%) patients receiving chlorambucil alone and in 2749 (55%) patients receiving the combination (P = NS). Preliminary analysis of remission duration shows a trend in favour of those patients receiving interferon throughout (P = 0.02). There is no significant difference between the groups in terms of survival, at a median follow up of 2.5 years. Interferon-associated toxicity was minor in most patients but led to discontinuation of therapy in six cases. Larger trials with longer follow-up periods are needed to confirm the beneficial role of interferon in the treatment of follicular lymphoma.

干扰素α -2b加氯霉素治疗滤泡性淋巴瘤:一项正在进行的随机试验的初步结果
124例滤泡性淋巴瘤患者(32例为III期,92例为IV期)被随机分为单独使用氯霉素或氯霉素加干扰素α -2b组。应答的患者随后随机接受干扰素α -2b维持治疗长达12个月或不接受进一步治疗。108名患者可评估反应,其余患者仍在接受初始治疗。4259例(71%)单独使用氯苯丁二烯的患者和2749例(55%)联合使用氯苯丁二烯的患者达到临床缓解(完全或部分缓解)(P = NS)。缓解持续时间的初步分析显示,患者在整个过程中接受干扰素治疗的趋势更有利(P = 0.02)。两组患者的生存期无显著差异,平均随访时间为2.5年。干扰素相关毒性在大多数患者中较轻,但在6例患者中导致停药。需要更大的试验和更长的随访期来证实干扰素在治疗滤泡性淋巴瘤中的有益作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信